-60.0 lbs
Based on Phase 2 trial data, the most common early side effects are nausea, vomiting, diarrhoea, constipation, and reduced appetite, consistent with the GLP-1 receptor agonist class
In 2016, 650 million people were obese and in 2020, 39 million children under the age of 5 were already overweight or obese ( Current guidelines for the treatment of diabetes and obesity recommend a step-wise approach starting with lifestyle interventions aimed at body weight loss, an increase in physical activity, and additional measures for healthier choices in everyday decisions and habits

Primary candidates for GLP-1 therapy include: Patients with type 2 diabetes and inadequate glycemic control despite metformin therapy Individuals with type 2 diabetes and established atherosclerotic cardiovascular disease Patients with type 2 diabetes and multiple cardiovascular risk factors (hypertension, dyslipidemia, obesity) Adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with weight-related comorbidities Patients with metabolic syndrome who have not achieved adequate risk factor control with lifestyle modification For patients with dyslipidemia, GLP-1 agents may be particularly valuable when combined with statin therapy in those who have not reached LDL-C goals or who have persistent hypertriglyceridemia despite statin treatment
After the initial adjustment phase, deliberately expand your food repertoire
Researchers sourcing peptides from international suppliers often face extended shipping times that challenge cold chain maintenance